Daclatasvir

Daclatasvir is an NS5A replication complex inhibitor used in the treatment of chronic Hepatitis C virus (HCV) infection. It acts by binding to the NS5A protein, preventing viral RNA replication and virion assembly. Mediocon Inc supplies pharmaceutical-grade Daclatasvir meeting IP, BP, EP, and USP standards.

Key Features

• Analgesic, antipyretic & anti-inflammatory
• USP/BP/IP compliant quality
• Widely used in cardiovascular therapy
• Suitable for tablet and effervescent formulations

Applications

• Chronic Hepatitis C (all genotypes)
• Direct-acting antiviral (DAA) regimens
• Combination HCV therapy formulations
• Antiviral R&D applications

Why Choose Mediocon

• ISO 9001:2015 & GMP certified manufacturing
• Consistent batch-to-batch quality with full CoA
• Export-ready documentation: COO, MSDS, DMF
• Flexible MOQ for both R&D and commercial scale
• Dedicated QA support for regulatory filings